Hugo Botha

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9283788/publications.pdf

Version: 2024-02-01

94 papers	2,343 citations	201674 27 h-index	254184 43 g-index
96 all docs	96 docs citations	96 times ranked	2441 citing authors

#	Article	IF	Citations
1	Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia. Journal of the International Neuropsychological Society, 2022, 28, 441-451.	1.8	1
2	Autopsy Validation of Progressive Supranuclear Palsyâ€Predominant Speech/Language Disorder Criteria. Movement Disorders, 2022, 37, 213-218.	3.9	6
3	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	3.3	15
4	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition. Acta Neuropathologica Communications, 2022, 10, 16.	5.2	14
5	Tractography of supplementary motor area projections in progressive speech apraxia and aphasia. NeuroImage: Clinical, 2022, 34, 102999.	2.7	11
6	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	3.6	7
7	A computational model of neurodegeneration in Alzheimerâ€™s disease. Nature Communications, 2022, 13, 1643.	12.8	32
8	A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia. Brain Sciences, 2022, 12, 378.	2.3	1
9	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	3.9	11
10	Depression and Apathy across Different Variants of Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2022, 9, 212-217.	1.5	8
11	Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy. Movement Disorders, 2022, 37, 702-712.	3.9	14
12	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimerâ€™s disease. Acta Neuropathologica, 2022, 143, 571-583.	7.7	3
13	Posterior Cingulate Involvement Does Not Argue Against LATE. Journal of Nuclear Medicine, 2022, 63, 1282-1283.	5.0	0
14	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	3.3	5
15	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	11.6	52
16	Cross-Sectional and Longitudinal Assessment of Behavior in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. Dementia and Geriatric Cognitive Disorders, 2022, 51, 193-202.	1.5	1
17	Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant. NeuroImage: Clinical, 2022, 35, 103030.	2.7	8
18	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimerâ€™s Disease. Cerebral Cortex, 2021, 31, 1693-1706.	2.9	44

#	Article	IF	Citations
19	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	4.2	63
20	Neurobehavioral Characteristics of FDG-PET Defined Right-Dominant Semantic Dementia: A Longitudinal Study. Dementia and Geriatric Cognitive Disorders, 2021, 50, 17-28.	1.5	5
21	A Longitudinal Evaluation of Speech Rate in Primary Progressive Apraxia of Speech. Journal of Speech, Language, and Hearing Research, 2021, 64, 392-404.	1.6	7
22	Diffusion tensor imaging analysis in three progressive supranuclear palsy variants. Journal of Neurology, 2021, 268, 3409-3420.	3.6	12
23	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	2.6	8
24	Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses. Journal of Neurology, 2021, 268, 4752-4758.	3.6	5
25	A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech. Nature Communications, 2021, 12, 3452.	12.8	34
26	Motor Speech Disorders and Communication Limitations in Progressive Supranuclear Palsy. American Journal of Speech-Language Pathology, 2021, 30, 1361-1372.	1.8	12
27	Gray and White Matter Correlates of Dysphagia in Progressive Supranuclear Palsy. Movement Disorders, 2021, 36, 2669-2675.	3.9	4
28	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	3.3	12
29	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î² PET Signal. Neurology, 2021, 97, e1799-e1808.	1.1	10
30	Assessing Change in Communication Limitations in Primary Progressive Apraxia of Speech and Aphasia: A 1-Year Follow-Up Study. American Journal of Speech-Language Pathology, 2021, 30, 1-11.	1.8	1
31	Sleep disturbances in the speech-language variant of progressive supranuclear palsy. Parkinsonism and Related Disorders, 2021, 91, 9-12.	2.2	4
32	Relationships between Î²-amyloid and tau in an elderly population: An accelerated failure time model. NeuroImage, 2021, 242, 118440.	4.2	15
33	Survival Analysis in Primary Progressive Apraxia of Speech and Agrammatic Aphasia. Neurology: Clinical Practice, 2021, 11, 249-255.	1.6	9
34	Neuroimaging correlates of gait abnormalities in progressive supranuclear palsy. NeuroImage: Clinical, 2021, 32, 102850.	2.7	13
35	Changes in Ventricular and Cortical Volumes following Shunt Placement in Patients with Idiopathic Normal Pressure Hydrocephalus. American Journal of Neuroradiology, 2021, , .	2.4	2
36	An examination of atypical primary progressive aphasia variants. Alzheimer's and Dementia, 2021, 17, .	0.8	0

#	Article	IF	Citations
37	Dysphagia in Progressive Supranuclear Palsy. Dysphagia, 2020, 35, 667-676.	1.8	25
38	Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech. Cortex, 2020, 124, 33-43.	2.4	5
39	The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study. Parkinsonism and Related Disorders, 2020, 81, 34-40.	2.2	20
40	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	7.6	74
41	Dementia with Lewy bodies presenting as Logopenic variant primary progressive Aphasia. Neurocase, 2020, 26, 259-263.	0.6	6
42	Longitudinal Amyloid-Î² PET in Atypical Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2020, 74, 377-389.	2.6	7
43	Sensitivityâ€“Specificity of Tau and Amyloid Î² Positron Emission Tomography in Frontotemporal Lobar Degeneration. Annals of Neurology, 2020, 88, 1009-1022.	5.3	32
44	Disrupted brain dynamics across the Alzheimerâ€™s disease spectrum is related to tau accumulation. Alzheimer's and Dementia, 2020, 16, e040583.	0.8	0
45	Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. Journal of Neurology, 2020, 267, 2603-2611.	3.6	12
46	Progressive dysexecutive syndrome due to Alzheimerâ€™s disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	3.3	81
47	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.1	27
48	Longitudinal flortaucipir ([18F]AV-1451) PET uptake in semantic dementia. Neurobiology of Aging, 2020, 92, 135-140.	3.1	3
49	Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. NeuroImage: Clinical, 2020, 25, 102152.	2.7	46
50	Western Aphasia Batteryâ€“Revised Profiles in Primary Progressive Aphasia and Primary Progressive Apraxia of Speech. American Journal of Speech-Language Pathology, 2020, 29, 498-510.	1.8	24
51	Communication Limitations in Patients With Progressive Apraxia of Speech and Aphasia. American Journal of Speech-Language Pathology, 2020, 29, 1976-1986.	1.8	13
52	Clinical and neuroimaging characteristics of clinically unclassifiable primary progressive aphasia. Brain and Language, 2019, 197, 104676.	1.6	29
53	Multimodal neuroimaging relationships in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2019, 66, 56-61.	2.2	19
54	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. Mayo Clinic Proceedings, 2019, 94, 1516-1523.	3.0	35

#	Article	IF	Citations
55	The bivariate distribution of amyloid-Î² and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	7.6	129
56	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	7.6	37
57	Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome. Brain, 2019, 142, 2466-2482.	7.6	33
58	Utility of the Movement Disorders Society Criteria for Progressive Supranuclear Palsy in Clinical Practice. Movement Disorders Clinical Practice, 2019, 6, 436-439.	1.5	10
59	An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Movement Disorders Clinical Practice, 2019, 6, 452-461.	1.5	26
60	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	3.9	98
61	ICâ€Pâ€022: BRAIN STATES AND TAU PET PATTERNS INTERACT ACROSS THE AGINGâ€ALZHEIMER'S CONTINUUM. Alzheimer's and Dementia, 2019, 15, P30.	0.8	0
62	Cerebral microbleeds. Neurology, 2019, 92, e253-e262.	1.1	53
63	MRI Outperforms [18F]AVâ€1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 105-113.	3.9	33
64	The influence of Î²-amyloid on [¹⁸ F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.1	10
65	Primary Progressive Aphasias and Apraxia of Speech. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 101-127.	0.8	29
66	[¹⁸F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	5.3	73
67	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.1	24
68	Disrupted functional connectivity in primary progressive apraxia of speech. NeuroImage: Clinical, 2018, 18, 617-629.	2.7	36
69	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	7.6	67
70	ICâ€Pâ€028: VARIABILITY IN PDMN CONNECTIVITY AND RELATIVE HUBNESS IN COGNITIVELY NORMAL INDIVIDUALS PREDICT AMYLOID AND TAU DEPOSITION PATTERNS IN TYPICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P32.	0.8	0
71	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	1.9	4
72	P1â€442: VARIABILITY IN PDMN CONNECTIVITY AND RELATIVE HUBNESS IN COGNITIVELY NORMAL INDIVIDUALS PREDICT AMYLOID AND TAU DEPOSITION PATTERNS IN TYPICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P480.	0.8	0

#	Article	IF	Citations
73	Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon?. Journal of the Acoustical Society of America, 2018, 144, 3364-3370.	1.1	5
74	Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech. European Journal of Neurology, 2018, 25, 1352-1357.	3.3	12
75	18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. NeuroImage: Clinical, 2018, 18, 897-902.	2.7	33
76	Prosodic and phonetic subtypes of primary progressive apraxia of speech. Brain and Language, 2018, 184, 54-65.	1.6	106
77	Non-right handed primary progressive apraxia of speech. Journal of the Neurological Sciences, 2018, 390, 246-254.	0.6	4
78	Functional Connectivity in Dementia. , 2018, , 245-266.		2
79	Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase, 2018, 24, 111-120.	0.6	25
80	Facial diplegia after pembrolizumab treatment. Muscle and Nerve, 2017, 56, E20-E21.	2.2	22
81	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	2.4	162
82	NeuroDebian Virtual Machine Deployment Facilitates Trainee-Driven Bedside Neuroimaging Research. Journal of Child Neurology, 2017, 32, 29-34.	1.4	0
83	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	1.9	2
84	A Young Man With Progressive Language Difficulty and Early-Onset Dementia. JAMA Neurology, 2016, 73, 595.	9.0	0
85	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. Cortex, 2015, 69, 220-236.	2.4	133
86	Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech. Neurology, 2014, 82, 1729-1735.	1.1	63
87	Clinical Reasoning: A woman with subacute progressive confusion and gait instability. Neurology, 2014, 83, e62-7.	1.1	1
88	The pimple sign of progressive supranuclear palsy syndrome. Parkinsonism and Related Disorders, 2014, 20, 180-185.	2.2	32
89	Teaching Neuro Images : Massive cerebral edema after CT myelography. Neurology, 2014, 83, e170.	1.1	0
90	FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants. Journal of Neurology, 2014, 261, 710-716.	3.6	60

#	Article	IF	Citations
91	Consensus recommendations for the prevention of cervical cancer in sub-Saharan Africa. Southern African Journal of Gynaecological Oncology, 2013, 5, 47-57.	0.3	4
92	Attention and visual dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, 742-747.	2.2	45
93	Comparison of 2 Dementia Screeners, the Test Your Memory Test and the Mini-Mental State Examination, in a Primary Care Setting. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 85-88.	2.3	22
94	Reliability and Diagnostic Performance of CT Imaging Criteria in the Diagnosis of Tuberculous Meningitis. PLoS ONE, 2012, 7, e38982.	2.5	39